Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 9/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587949 | 1.00 | RORC (0.46) | RORCALDH1A1SMN1; SMN2P2RX4PDE4B | |
| SCHEMBL24313728 | 0.86 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PDE4BTSHRKMT2A | |
| SCHEMBL29469921 | 0.86 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2PDE4BTSHRKMT2A | |
| SCHEMBL22587894 | 0.82 | ALDH1A1 (0.41) | RORCALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL29588404 | 0.82 | ALDH1A1 (0.41) | RORCALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL29469893 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL22588350 | 0.80 | ALDH1A1 (0.47) | RORCALDH1A1SMN1; SMN2P2RX4 | |
| SCHEMBL1438963 | 0.79 | NPC1 (0.50) | SMN1; SMN2PDE4BTSHRKMT2APDE4A | |
| SCHEMBL16852267 | 0.77 | PDE4B (0.43) | ALDH1A1SMN1; SMN2PDE4BPDE4APDE4C | |
| SCHEMBL22588464 | 0.77 | P2RX4 (0.43) | ALDH1A1SMN1; SMN2P2RX4PDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114072394-A | Acylsulfonamides for the treatment of cancer | 拜耳股份公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | RORC 3566/4885ALDH1A1 1125/4885SMN1; SMN2 3153/4885 |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | RORC 2800/4885ALDH1A1 1645/4885SMN1; SMN2 3423/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | RORC 2800/4885ALDH1A1 1645/4885SMN1; SMN2 3423/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | RORC 2619/4885ALDH1A1 985/4885SMN1; SMN2 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.